Efren Guillermo Delos Santos

This inventor holds 21 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: American Cyanamid Company, Wyeth, Pfizer Corporation. Active years: 1996-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Efren Guillermo Delos Santos. Retrieved from https://idiyas.com/inventor/efren-guillermo-delos-santos

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21

% Patents Active = 95.2

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 4.3

ph-index = 7

Forward Citations = 180(Granted Patents)

Company Filing History:

12 out of 3,580

American Cyanamid Company

Wyeth Holdings Corporation

patents

Years Active: 1996-2018

Loading Chart...

Areas of Expertise:

Triazine Compounds

PI3 Kinase

mTOR Inhibitors

Matrix Metalloproteinase

TACE Inhibitors

Vasopressin Antagonists

Oxytocin Antagonists

Hydroxamic Acids

Benzodiazepines

Thieno-Azepines

Diazepine Compounds

Aryl Sulfonamide

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10022381 - Triazine compounds as PI3 kinase and mTOR inhibitors (2018-07-17),

2. 9174963 - Triazine compounds as PI3 kinase and MTOR inhibitors (2015-11-03),

3. 8859542 - Triazine compounds as PI3 kinase and mTOR inhibitors (2014-10-14),

4. 8748421 - Triazine compounds as P13 kinase and MTOR inhibitors (2014-06-10),

5. 8575159 - Triazine compounds as PI3 kinase and mTOR inhibitors (2013-11-05),

6. 8445486 - Triazine compounds as PI3 kinase and mTOR inhibitors (2013-05-21),

7. 8217036 - Triazine compounds as PI3 kinase and mTOR inhibitors (2012-07-10),

8. 8039469 - Triazine compounds as PI3 kinase and mTOR inhibitors (2011-10-18),

9. 7282496 - Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors (2007-10-16),

10. 6544984 - 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids (2003-04-08),

11. 6071903 - 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids (2000-06-06),

12. 5968937 - Tricyclic diazepine vasopressin antagonists and oxytocin antagonists (1999-10-19),

13. 5968930 - Tricyclic diazepine vasopressin antagonists and oxytocin antagonists (1999-10-19),

14. 5889001 - Tricyclic diazepine vasopressin antagonists and oxytocin antagonists (1999-03-30),

15. 5854237 - Tricyclic diazepine vasopressin antagonists and oxytocin antagonists (1998-12-29),

Title: Efren Guillermo Delos Santos: Innovator in Oncology Therapeutics

Introduction

Efren Guillermo Delos Santos, based in Nanuet, NY, has made significant contributions to the field of medicinal chemistry, with a total of 21 patents to his name. His work focuses on the development of innovative compounds aimed at treating various cancers through inhibition of critical biological pathways.

Latest Patents

Delos Santos' latest patents include the development of triazine compounds designed as PI3 kinase and mTOR inhibitors. These compounds, characterized by specific formulas and pharmaceutically acceptable salts and esters, show potential in treating diseases mediated by the PI3 kinase and mTOR pathways, particularly different types of cancers. The patents disclose methods for synthesizing and utilizing these compounds, as well as various compositions that incorporate them, paving pathways for new therapeutic options.

Career Highlights

Throughout his career, Delos Santos has been affiliated with prestigious organizations, including American Cyanamid Company and Wyeth. His work has contributed to advancing therapeutic strategies in cancer treatment, solidifying his role as a prominent figure in pharmaceutical innovation.

Collaborations

In his journey as an inventor, Delos Santos has collaborated with notable individuals such as Jay Donald Albright and Aranapakam Mudumbai Venkatesan. These partnerships have likely fostered a rich exchange of ideas and innovations in their shared pursuit of medical advancements.

Conclusion

Efren Guillermo Delos Santos stands out as a dedicated inventor in the field of oncology, demonstrating a commitment to developing effective treatments through his creative research and innovative compounds. His work continues to influence cancer therapeutics significantly, providing hope for more effective treatment options in the future.

Profile summary based on public USPTO records.